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ABSTRACT
Resistance to radiation therapy is a significant problem in the treatment of nonsmall cell lung cancer (NSCLC). There is an unmet need to discover new molecular
targets for drug development in combination with standard of care cancer therapy.
We found that TAF15 was radiation-inducible using phage-displayed peptide libraries.
In this study, we report that overexpression of TAF15 is correlated with worsened
survival in NSCLC patients. Radiation treatment led to surface induction of TAF15 in
vitro and in vivo. We genetically silenced TAF15 which led to a significant reduction
in proliferation of NSCLC cells. Cells depleted of TAF15 exhibited cell cycle arrest and
enhanced apoptosis through activation and accumulation of p53. In combination with
radiation, TAF15 knockdown led to a significant reduction in the surviving fraction
of NSCLC cell lines. To determine the importance of TAF15 surface expression, we
targeted TAF15 with an antibody. In combination with radiation, the anti-TAF15
antibody led to a reduction in the surviving fraction of cancer cells. These studies
show that TAF15 is a radiation-inducible molecular target that is accessible to anticancer antibodies and enhances cell viability in response to radiation.

INTRODUCTION

identified TATA-box-binding protein-associated factor 15
(TAF15) as one protein that is expressed on the surface
of NSCLC cells following irradiation. TAF15 belongs
to a conserved FUS-EWS-TAF15 (FET) family of
RNA binding proteins, which are key regulators of gene
expression, including RNA splicing, polyadenylation,
capping, modification, export, localization, translation
and turnover [7, 8]. FET proteins are primarily present in
the nucleus [9]; however, they also shuttle between the
nucleus, cytoplasm, and the cell surface [10–12]. Thus,
FET proteins have an expanded functional repertoire
beyond DNA binding [13], RNA processing events like
pre-mRNA splicing and mRNA transport [14], regulation
[15] and interaction with a diverse number of proteins [16].
Under normal conditions, TAF15 controls cellular
viability through the regulation of cell cycle and cell
death-related genes [17]. Under conditions of cellular
stress, stress granules, which are aggregates of protein
and RNA (mostly untranslated mRNA), accumulate in
the cytosol. The formation of these dense aggregates of
protease-resistant complexes is needed to protect RNAs

Resistance to therapy is a significant challenge
during the treatment of non-small cell lung cancer
(NSCLC). NSCLC ranks among the most common type
of malignancy and is the leading cause of cancer-related
deaths worldwide [1, 2]. Although advancements in
diagnosis and treatment have improved the survival of
patients with lung cancer, the 5-year overall survival rate
of NSCLC is ~19% [3]. Thus, there is an unmet need to
develop novel treatment strategies for lung cancer patients.
The demand is even higher for patients who have locally
advanced, unresectable cancer. Targeted therapy is a
growing topic of investigation for improving the current
treatment strategies. The purpose of the present study is to
discover additional molecular targets that complement and
enhance the efficacy of standard of care chemotherapy and
radiation therapy (XRT).
Our lab discovered radiation-inducible surface
proteins by the use of phage-displayed peptide libraries
following irradiation (IR) of in vivo cancers [4–6]. We
www.oncotarget.com
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from degradation under cell stress [18]. TAF15, which
possesses an RNA-binding domain, has been shown to
co-localize to cytoplasmic stress granules in response to
both heat and oxidative stress [19].
A previous study showed that human antibody
PAT-BA4 that recognizes a variant of cell surface TAF15
inhibits cancer cell motility and cell adhesion in stomach
cancer and melanoma [20]. Inhibition of TAF15 showed
a growth-inhibitory effect and resulted in increased
apoptosis and decreased proliferation in cancer cells [17].
In the present study, we found that IR enhanced the surface
expression of TAF15 in NSCLC cell lines. We studied
the effect of anti-TAF15 antibody on cells with surface
associated TAF15, and its impact on cell survival when
combined with IR. The results demonstrate the feasibility
of targeting surface associated TAF15 as a strategy for the
improvement of therapeutic efficacy in NSCLC with IR.

following irradiation. A549 and H460 cells were either
irradiated with 3Gy or sham irradiated and harvested
at 24, 48, 72 and 96 h for staining with the anti-TAF15
antibody. Supplementary Figure 2A and 2B show the
overlay histograms of sham or 3Gy irradiated A549
and H460 cells, respectively. Bar graphs show that 5%
of sham-irradiated cells are positive for TAF15 surface
staining (Figure 2A and 2B). We found approximately a
3-fold increase in the percentage of TAF15 positive cells
in A549 (at 48–72 h) (Figure 2A) and H460 (72 h) (Figure
2B) lung cancer cells following 3Gy irradiation. TAF15
surface expression remained constant in sham-irradated
cells over 96 h (Figure 2A and 2B).
We also evaluated the surface expression of TAF15
in MRC5, normal lung cells. As with the cancer cells, we
either irradiated with 3Gy or sham irradiated MRC5 and
harvested cells at 24, 48 and 72 h for flow cytometry. We
found negligible upregulation of TAF15 on the surface of
MRC5 cells following irradiation. Supplementary Figure
3A shows overlay histograms of sham or 3Gy irradiated
MRC5 cells. Bar graphs show that only 3% cells exhibited
TAF15 surface expression following 3Gy IR at 48 and
72 h (Supplementary Figure 3B).

RESULTS
TAF15 is overexpressed and correlates with
worsened survival in NSCLC patients
To determine if the expression of TAF15 associated
with overall survival (OS) in NSCLC patients, we
analyzed the RNA-Seq data for cancer (Cancer Genome
Atlas (TCGA)) (3) and healthy tissue (Genotype-Tissue
Expression (GTEx)) (4,5) using the web-based Gene
Expression Profiling Interactive Analysis (GEPIA). Based
on the median expression level of TAF15, we grouped the
patients into two groups: “High” (n = 239) and “Low”
(n = 239). Figure 1A shows the Kaplan–Meier survival
curves representing the OS of lung adenocarcinoma
patients grouped according to their TAF15 expression
levels. Higher expression levels of TAF15 significantly
correlated (p = 0.035, HR = 1.4) with a worsened OS of
lung adenocarcinoma patients (Figure 1A). However, this
difference in survival was not observed until 2000 days,
and in the case of squamous cell carcinoma patients, we
did not find a correlation between TAF15 expression
levels and overall survival (Supplementary Figure 1A)
We next evaluated TAF15 expression in NSCLC
patients using a tumor tissue microarray (TMA) containing
NSCLC and matched healthy lung tissue (Figure 1B). The
TMA contained cancers from 30 patients and 10 matched
healthy tissue controls. We found high expression of
TAF15 in NSCLC (black arrows, Figure 1B) and that
expression levels correlated with increasing stage and
grade of lung cancer. We did not find expression of TAF15
in healthy tissues (Supplementary Figure 1B).

IR induces TAF15 in mouse models of NSCLC
We next evaluated whether radiation induces TAF15
in subcutaneous NSCLC xenografts. We injected A549 or
H460 cells into the hind limbs of nude mice to generate
subcutaneous tumors. Cancers were irradiated with three
fractions of 3Gy and compared to mice treated with sham
irradiation. Anti-TAF15 antibody conjugated to IRDye
800 was injected via tail vein, and whole-body NIR
imaging was performed (Figure 2C and 2D). Figure 2C
and Supplementary Figure 3C show representative images
of mice bearing A549 and H460, respectively. We found
a significantly higher expression of TAF15 (p < 0.0001)
following IR as compared to the isotype control antibody
(Figure 2D) over several days. Following NIR imaging,
we evaluated the microscopic biodistribution of the antiTAF15 antibody in frozen cancer sections (Figure 2E).
We found an enhanced accumulation of anti-TAF15
antibody in the irradiated tumors (white arrows) when
compared to sham irradiated tumors which had little or
no accumulation.

Co-immunoprecipitation studies with antiTAF15 antibody identify various roles of TAF15
in lung cancer
To identify the role TAF15 plays in lung cancer
cells, we performed co-immunoprecipitation of TAF15
from A549 and H460 lysates. We identified TAF15
interacting proteins using mass spectrometry. We found
326 TAF15 interacting proteins in sham irradiated lung
cancer cells vs. 703 proteins in irradiated (3Gy) cells.

IR induces expression of TAF15 on the surface of
cancer cells
We performed flow cytometry analysis to evaluate
cell surface expression of TAF15 in NSCLC cells
www.oncotarget.com
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Sham irradiated, and 3Gy irradiated samples shared
1760 interacting proteins (Figure 3A). For the identified
proteins, we performed Gene Ontology (GO) analysis
using the Ingenuity Pathway Analysis (IPA) software.
Figure 3B shows the list of significant (-log p-value
< 0.05) GO processes where TAF15 and its interacting
partners may be involved. The most significant GO
processes were RNA post-transcriptional modification,
protein synthesis, RNA damage and repair, cell death
and survival, cellular growth and proliferation, cell cycle
(Figure 3B). We found that TAF15 and its interacting
partners are localized in various cellular compartments,
including membrane, nucleus, ribosomes, and organelle
membranes (Figure 3C). IPA further identified possible
mediators of TAF15’s response to radiation. The top
predicted mediator was the TP53 (activation z-score 2.18)
encoding the p53 tumor suppressor protein (Figure 3D).

S, and G2). Figure 4C and 4E show the percentage of
cells in each phase of the cell cycle for A549 and H460
cells, respectively. Figure 4D and Figure 4F represent the
histograms showing the distribution of cells in different
phases of the cell cycle following TAF15 knockdown for
A549 and H460 cells, respectively. We observed arrest
in the G2/M and S phase of the cell cycle. In A549, we
found an increase from 7.38% (scrambled control) to
13.1% (sh1) and 12% (sh2) in the G2/M phase (p < 0.005)
(Figure 4C). For H460, cells in S phase increased from
28.8% (scrambled control) to 31.6% (sh1) and 35.8%
(sh2) (p < 0.005) (Figure 4E).
At the molecular level, we found enhanced
phosphorylation of cyclin-dependent kinase cdc2 at
Tyrosine15 residue following TAF15 knockdown
(Figure 4G). TAF15 knockdown also led to the
upregulation of phospho-Chk2 in A549 cells, while
little change was observed in H460 cells (Figure 4G).
We found the upregulation of phosphorylated levels
of p53 cancer suppressor in both A549 and H460 cells
following TAF15 knockdown (Figure 4G). We evaluated
the Serine795 and Serine807/811 phosphorylation of the
retinoblastoma protein (Rb) proteins and found a reduction
in phosphorylation at these residues in both A549 and
H460 cells following TAF15 knockdown (Figure 4G).
Furthermore, we observed the upregulation of the p21
protein after TAF15 knockdown (Figure 4G).

Genetic knockdown of TAF15 inhibits
proliferation by arresting the cell cycle in
NSCLC cell lines
To understand the role of TAF15 in NSCLC
progression, we used short-hairpin RNAs (shRNAs)
to knock down TAF15 in A549 and H460 cells. Two
shRNAs targeting TAF15 (sh1 and sh2) reduced TAF15
protein expression by 90% when compared to scrambled
shRNA (scr) as detected by western blot analysis (Figure
4G). TAF15 knockdown led to a significant reduction (p
< 0.0001) in the proliferation of A549 and H460 cells in a
time-dependent manner (Figure 4A and 4B). To evaluate
whether the attenuation of proliferation following TAF15
knockdown was due to cell cycle arrest, we analyzed DNA
content to determine the phases of the cell cycle (G0/G1,

Genetic knockdown of TAF15 induces apoptosis
in NSCLC cell lines
To evaluate the role of TAF15 in cell death in A549
and H460, we measured apoptosis following TAF15
knockdown. Annexin V staining was performed to assess

Figure 1: TAF15 is overexpressed in NSCLC that correlates to poor overall survival. (A) Kaplan Meier survival curves

showing the overall survival of lung adenocarcinoma patients grouped according to their TAF15 expression levels. The survival curves
were generated using the GEPIA web-browser by analyzing the TCGA RNA-Seq dataset. Patients were grouped into “High” (n = 239) and
“Low” (n = 239) based on the median expression level of TAF15. High levels of TAF15 significantly correlated (p = 0.035, HR = 1.4) with
poor overall survival of lung cancer patients. (B) Immunohistochemistry analysis of lung tumor tissue microarray showing expression of
TAF15 in lung cancers having matched healthy tissues. The tumor tissue microarray contained cancers from 30 patients and 10 matched
healthy tissue controls. Each section was represented in duplicate on the tissue array. Representative images are shown and the numbers in
the parenthesis indicate the stage of cancer.
www.oncotarget.com
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the percentage of cells undergoing apoptosis. Figure 5A
shows representative dot plots for A549 and H460
showing Annexin V single positive (early apoptosis) and
Annexin V- propidium iodide (PI) double-positive (late
apoptosis) cells. TAF15 knockdown with both shRNAs
led to a significant increase (p < 0.001) in the percentage
of cells undergoing early and late stages apoptosis in A549
(Figure 5B). In H460 cells, shRNA2 led to a significant
increase (p < 0.001) in apoptosis, whereas, shRNA1
did not show a significant difference compared to the
scrambled control (Figure 5C).
We probed for known mediators of apoptosis
using western blotting. We found enhanced cleavage of
the effector caspases 3 and 7 in A549 and H460 cells
following TAF15 knockdown (Figure 5D). We did not

observe much change in the levels of the initiator caspase
9. We found the accumulation of the cleaved fragment
of PARP in A549 cells depleted of TAF15 (Figure 5D).
These studies further confirm that TAF15 protects A549
and H460 from apoptosis.

Antibody targeting TAF15 enhances cytotoxicity
in NSCLC cell lines
We hypothesized that TAF15 induction following
radiation might lead to enhanced cancer cell survival.
We, therefore, investigated whether TAF15 knockdown
leads to enhanced radiation cytotoxicity in NSCLC
cells. We performed colony formation assays with cells
having knockdown of TAF15 following irradiation (0,

Figure 2: TAF15 is induced by radiation in vitro and in vivo. (A–B) Flow cytometry analysis of cell surface expression of TAF15

in A549 (A) and H460 (B) cells. NSCLC cells either were irradiated with 3Gy or sham and harvested at 24, 48, 72 and 96 h following
irradiation. Cells were stained with anti-TAF15 antibody and bar diagram showing the percentage of TAF15 positive cells are plotted
against the times. A two to three-fold increase in the percentage of TAF15 positive cells was observed following irradiation in both cell
lines. (C) Representative NIR fluorescence images of nude mice after intravenous injection of IRDye 800 labeled TAF15 antibody at
indicated time points. Mice were injected with A549 cells in the right hind limb and allowed to grow to 1 cm3 volume. Cancers were either
sham irradiated or irradiated with three doses of 3Gy irradiation over a course of 24 h. Each group had three mice. Representative images
are shown along with the scale bar. (D) Line graph showing background-subtracted fluorescence intensity of IRDye800 in sham irradiated
and 3Gy × 3 irradiated A549 cancers over time compared to the isotype control. Blue lines indicate fluorescence intensity of isotype control
antibody, red line and green line indicate fluorescence intensity of TAF15 antibody in 3Gy × 3 irradiated and sham irradiated cancers,
respectively. Data are means ± s.e.m. (n = 3 mice). *p < 0.05, ****p < 0.0001. (E) Microscopic biodistribution of the anti-TAF15 antibody
in A549 cancers harvested from the hind limbs of nude mice following NIR imaging. White arrows indicate the presence of anti-TAF15
antibody (red). Nuclei were stained with DAPI and shown in blue. CD31 staining is shown in green.
www.oncotarget.com
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2, 4, 6 and 8Gy) (Supplementary Figure 3D and 3E). We
found a reduction in the surviving fraction of the TAF15
knockdown cells with increasing doses of radiation
(Supplementary Figure 3D and 3E). Both A549 and H460
cells with TAF15 knockdown lost the ability to form
colonies at the highest dose of radiation. Representative
bar graphs at 6Gy are shown in Figure 6A and 6B.
We targeted TAF15 with a blocking antibody
to determine the feasibility of developing a molecular
target for the treatment of cancer. Similar to the shRNA
mediated knock-down, an anti-TAF15 antibody produced
a significant reduction (p < 0.001) in the surviving fraction
of A549 cells (Figure 6C) and H460 cells (Figure 6D)
compared to the isotype control. Radiation added to the
anti-TAF15 antibody-treated cells further reduced the
surviving fraction in both cell lines as compared to the
isotype control (p < 0.001) (Figure 6C and 6D). To evaluate
the target specificity of the anti-TAF15 monoclonal
antibody, we treated the cells having TAF15 knockdown

with the anti-TAF15 monoclonal antibody or isotype
control antibody. The anti-TAF15 antibody significantly
reduced the cell viability of scrambled shRNA containing
cells compared to the isotype control (Figure 6E and 6F).
The anti-TAF15 antibody did not affect the cells having
TAF15 knockdown, indicating the specific targeting by the
ant-TAF15 antibody in NSCLC cells.
AKT is the master regulator of cell survival. We
found the downregulation of phosphorylated levels of
AKT following TAF15 knockdown (Figure 6G). Radiation
slightly enhanced p-AKT in both cells. However, TAF15
knockdown abrogated the radiation induction of p-AKT
(Figure 6G). We found little change in the total-AKT
levels in any of the treatment groups. We also evaluated
phosphorylated and total AKT levels in NSCLC cells
following TAF15 antibody treatment. Attenuation in
p-AKT was found in A549 and H460 in response to
antibody treatment. Total AKT levels were unchanged in
A549 cells, as compared to a slight decrease observed in

Figure 3: Co-immunoprecipitation studies with anti-TAF15 antibody identify various roles of TAF15 in lung cancer.
A549 and H460 cells were irradiated, and TAF15 interacting partners were pulled down with an anti-TAF15 antibody. (A) Venn diagram
showing several proteins that were pulled down in irradiated vs. non-irradiated samples. (B) Ingenuity pathway analysis of the pulled
proteins identifies the involvement of TAF15 in various molecular functions. (C) Pie chart showing that TAF15 binding partners belong to
various cellular components. (D) Predicted regulators of TAF15’s response to radiation identified by Ingenuity Pathway Analysis software.
www.oncotarget.com
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H460 cells following antibody treatment (Supplementary
Figure 3F).
Based on the observations above and previous
studies, we propose that TAF15 plays a protective role and
mediates resistance to radiation therapy by inhibiting the
tumor suppressors p53 and p21 (Figure 6H).

repair, and RNA maturation. The FET family of proteins
is involved in carcinogenesis; however, most of these
studies have focused on FUS and EWS [17, 21, 22].
Not much is known about TAF15 in lung cancer. In the
TCGA RNA-Seq lung adenocarcinoma patient dataset,
although a difference in survival was not observed until
2000 days, none of the patients having high TAF15
levels in their cancer survived, as compared to 30%
overall survival in patients with low levels of TAF15
(Figure 1). We did not find a correlation between TAF15
expression levels and overall survival of squamous cell
carcinoma patients (Supplementary Figure 1A). RNA
Sequencing data for other histological subtypes (large cell

DISCUSSION
TAF15 belongs to the FET family of RNA and
DNA binding proteins. These proteins are involved
in transcriptional and post-transcriptional regulatory
processes such as transcription initiation, splicing, DNA

Figure 4: TAF15 silencing inhibits NSCLC proliferation by arresting the cell cycle. (A–B) Cell proliferation of A549 and

H460 cells was monitored after the silencing of TAF15. An equal number of cells were seeded and counted at 24, 48, 72, and 96 hours.
Graphs show normalized fold change vs. time in hours. ****P < 0.001. Data represent three independent experiments. C-F Cell cycle analysis
following the silencing of TAF15 in A549 (C and D) and H460 (E and F) cells. Representative histograms showing the different phases (G1:
blue, S: yellow and G2: green) of cell cycle are shown in D and F and the corresponding frequencies of cells in each phase are represented
in tables in C and E. (G) Western blot analysis for the expression of protein levels of various cell cycle regulators. Densitometric analysis
was performed using the ImageJ software, and the numbers below the blots represent densities normalized to Tubulin (loading control).
www.oncotarget.com

2652

Oncotarget

and small cell carcinoma) is not available from TCGA.
Immunohistochemistry analysis of lung cancer TMA
revealed a higher expression of TAF15 when compared
to matched healthy lung tissue (Figure 1). Thus, TAF15
protein is overexpressed in lung cancer, and this elevated
expression level correlates with cancer death.
Previously, we discovered TAF15 as a radiationinducible lung cancer surface protein by the use of

phage-displayed peptide libraries [4–6]. We performed
flow cytometry analysis on non-permeabilized cells to
measure the enhanced surface expression after irradiation
of NSCLC. We found that irradiation of A549 and H460
cells increased the percentage of TAF15 positive cells by
approximately 3-fold compared to sham-irradiated cells
(Figure 2A and 2B). However, irradiation of normal lung
cells, MRC5, showed negligible upregulation of TAF15

Figure 5: TAF15 silencing induces apoptosis in A549 and H460 cells. (A) Annexin V-PI staining was performed to detect

apoptosis after TAF15 knockdown. Dot plots showing annexin-FITC on the x-axis and PI on the y-axis are shown. FITC and PI-positive
cells (Q2, double-positive) represent late apoptosis, and FITC positive (Q3, single positive) cells represent early apoptosis. (B and C) Bar
diagrams showing late apoptosis (black bars) and early apoptosis (grey bars) in A549 (B) and H460 (C) cells. Mean and SD is from three
independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001. (D) Western blot analysis for the expression of proteins involved in the
apoptotic pathways. Densitometry analysis was performed using the ImageJ software and the numbers below the blots represent densities
normalized to Tubulin (loading control).
www.oncotarget.com
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on the surface (Supplementary Figure 3A and 3B). These
data indicate that low dose radiation allows enhanced
TAF15 surface translocation in NSCLC cells compared to
normal tissue cells. Radiation-induced surface expression
of TAF15 will facilitate selective targeting of cancer
by therapeutic antibodies and minimizing normal lung
toxicity.
Moreover, cancer-specific binding of an antiTAF15 antibody labeled with near-infrared dye was
found during whole-animal imaging. Enhanced binding
of the anti-TAF15 antibody was observed in both cancer
models following irradiation. This improved binding of
the antibody in the irradiated cancers began at 24 h after
IR and persisted beyond four days (Figure 2C and 2D).
Furthermore, the microscopic biodistribution revealed
that the anti-TAF15 antibody distributed throughout
cancer (Figure 2E). The biodistribution of the anti-

TAF15 antibody throughout cancer sections demonstrates
potential bioavailability in tumor therapy.
The co-immunoprecipitation and mass spectrometry
revealed that TAF15 was interacting with proteins that
localized to various cellular compartments, including
the nucleus, cytoplasm, cell membrane and extracellular
regions (Figure 3C). TAF15 likely localizes to the cell
surface either in a complex or through the interactions
with proteins present on the cell surface. Ingenuity
pathway analysis also identified possible regulators
of TAF15 response to radiation. We found a predicted
upregulation of p53 (activation z-score 2.18), leading to
the downregulation of cell cycle regulators.
To study the role of TAF15 in response to radiation,
we knock down the protein in both A549 and H460 cells.
Silencing of TAF15 led to a significant reduction in
proliferation of NSCLC cells in a time-dependent manner

Figure 6: TAF15 silencing and anti-TAF15 antibody treatment sensitize NSCLC cells to radiation. (A–B) Colony formation

assay performed on TAF15 knockdown cells. Representative bar grpahs at 6Gy showing log10 surviving fraction are plotted. The silencing
of TAF15 sensitizes A549 cells (A) and H460 cells (B) to radiation. C-D Anti-TAF15 antibody treatment inhibits the proliferation of A549
(C) and H460 (D) cells and sensitizes them to radiation. Bar diagram showing the surviving fraction of A549 and H460 after TAF15ab in
combination with 3Gy radiation. (E–F) TAF15 knockdown abrogates the effect of the TAF15 antibody on cell proliferation. A549 and H460
cells having TAF15 knockdown were treated with TAF15 antibody or isotype control and cell proliferation was evaluated by trypan blue dye
exclusion assay at 96 h. Shown are the mean percentages of proliferating cells relative to the isotype treated scramble control. Mean, and
SD represents three independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001. (G) Western blot analysis for the expression of p-AKT
(Ser473) and total AKT protein levels. Densitometry analysis was performed using the ImageJ software, and the numbers below the blots
represent densities normalized to GAPDH (loading control). (H) Proposed mechanism of TAF15’s response to radiation in NSCLC. TAF15
knockdown leads to upregulation of p53 tumor suppressor which inhibits cell survival. P53 upregulates p21 that leads to cell cycle arrest.
www.oncotarget.com
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(Figure 4A and 4B). Similar observations were made in
HeLa cells, in which TAF15 was found to be essential for
proliferation and regulation of cell cycle genes through
microRNAs [17].
In our study, we found that the cells were arrested
in the S and G2/M phase of the cell cycle (Figure 4). In
the A549 cells, cells arrested in the G2/M phase, whereas
in the H460 cells, the arrest was in the S phase of cell
cycle. These subtle differences may be attributed to the
differences in the cellular origin and gene signatures of
these two cell lines [23]. Activated Chk2 can regulate
cell cycle arrest in late G1, S, and G2 phases through
phosphorylation of substrates such as Cdc25A and
Cdc25C [24–26]. Furthermore, activated Chk2 can
regulate not only p53-mediated apoptosis but also
p53-independent apoptosis [27]. Phosphorylation of
Cdc25A leads to its degradation and thereby sustained
inhibitory phosphorylation of Cdc2 (cyclin-dependent
kinase 1, Cdk1). In our study, we found enhanced Chk2
phosphorylation and enhanced phosphorylated levels
of Cdc2 following TAF15 knockdown (Figure 4G).
Unexpectedly, we observed decreased phosphorylation
of cdc2 in H460 cells transfected with shRNA1.
Phosphorylated Cdc2 cannot activate the Cdc2/cyclin B
complex, leading to an S-phase delay or G2 arrest [26].
The active hypophosphorylated forms of RB family
members block entry into the S phase by inhibiting
the E2F transcriptional program [28]. We found
phosphorylated levels of the Rb protein downregulated
following TAF15 knockdown in both A549 and H460
cells (Figure 4G). Phosphorylated p53 levels upregulated
with TAF15 knockdown. However, both TAF15 shRNAs
did not produce similar levels of p-p53 upregulation.
We also found the upregulation of p21 following TAF15
knockdown in A549 cells (Figure 4G). On the other hand,
H460 cells unexpectedly showed a decrease in p21 levels
following TAF15 knockdown. p21 binds to and inhibits
the activity of cyclin-CDK2, -CDK1 and –CDK4/6 and
thus regulates the G1 and S phase of the cell cycle [29,
30]. p21 may have been activated via p53, which is a
known activator of p21 [31, 32]. p21 downregulation has
been found to induce apoptosis [33–35]. We also found
that TAF15 depletion resulted in programmed cell death
in A549 and H460 cells (Figure 5A–5C). Apoptosis
was mediated by the cleavage of effector caspases 3
and 7, as detected by western blot analysis (Figure 5D).
PARP cleavage, which is an indicator of apoptosis, was
enhanced in A549 cells; however, we did not find much
accumulation in H460.
We next evaluated the importance of TAF15 in
response to radiation. We performed colony formation
assays and found a decrease in the surviving fraction in
irradiated cells that were depleted of TAF15 compared
to wild-type cells (Supplementary Figure 3D and 3E
and Figure 6A and 6B). We, therefore, looked at the
protein levels of phosphorylated AKT which is a wellwww.oncotarget.com

known master regulator of cell survival. p-AKT levels
were downregulated with TAF15 knockdown and further
depleted in combination with radiation. These studies
validated that TAF15 plays a protective role and prevents
cell death from radiation therapy.
TAF15 is a molecular target for drug development.
In a prior study, a human IgM anti-TAF15 antibody,
PAT-B4, isolated from a stomach cancer patient, targeted
a variant of TAF15 expressed on the surface of cancer
cells. PAT-BA4 inhibited migration and cell adhesion [20].
In our study, we targeted TAF15 with an antibody that is
specific to its ligand-binding domain. We found that the
antibody targeting TAF15 enhances the cytotoxicity of
cancer following irradiation. (Figure 6). TAF15 on the cell
surface may have a differential role from that of nucleus
bound TAF15. We evaluated AKT signaling following
treatment with the anti-TAF15 antibody and found a slight
decrease in p-AKT and total-AKT levels in NSCLC cells.
Further studies are needed to delineate the differential
roles of surface associated and nucleus bound TAF15.
TAF15 is a radiation-inducible molecular target
for the development of anti-cancer antibodies. Blocking
TAF15 with an antibody is a feasible approach to enhance
the cytotoxicity of radiation in NSCLC. This targeting
approach may lead to improved outcomes in NSCLC with
enhanced expression of TAF15.

MATERIALS AND METHODS
Cell lines, chemicals, antibodies and irradiation
Human NSCLC cell lines A549 and H460 were
obtained from ATCC and the normal lung cell line MRC5
was obtained from Sigma. A549 cells were cultured in
DMEM/F-12 and H460 in RPMI media containing 10%
fetal bovine serum (FBS) and 1% penicillin-streptomycin.
MRC5 cells were cultured in EMEM media containing
10% FBS, 2 mM glutamine, 1% non-essential amino
acids and 1% penicillin-streptomycin. All cell cultures
were grown in a humidified incubator at 37°C with 5%
CO2. All the cell lines were evaluated for mycoplasma
and tested negative. The cells and the mice were irradiated
with an RS2000 160kV X-ray Irradiator (Rad Source
Technologies, Suwanee, GA, USA). The anti-TAF15
antibody was obtained from Abcam. All other antibodies
were from cell signaling technologies. For knocking down
TAF15, three different short-hairpin RNA (shRNAs) were
obtained from Sigma (Saint Louis, USA).

Flowcytometry
Flow cytometry was performed as described earlier
[36]. Cells were either sham irradiated or irradiated with
3Gy and harvested at 24, 48, 72 and 96 h. Monoclonal
antibodies against human TAF15 and isotype control were
purchased from Abcam, USA. Anti-Rabbit Alexafluor488
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secondary antibody obtained from Invitrogen, USA. For
analysis of surface TAF15, cells were incubated with
antibodies in FACS staining buffer (PBS containing 5%
vol/vol FBS and 0.1% sodium azide). The expression level
was presented as a percentage, which was determined by
subtracting of isotype control. Results are presented as
overlay histograms and bar diagrams. Three individual
experiments were performed.

Apoptosis analysis was performed using the
Annexin V-FITC and PI kit (BD Biosciences) as per the
manufacturer’s protocol. After staining, the cells were
acquired in the MACSQuant Analyzer flow cytometer
(Miltenyi Biotech).

Immunohistochemistry

Cell proliferation assays

Immunohistochemistry for lung cancer (Origene)
and healthy tissue microarray (Biochain) was performed
as described earlier [41]. Briefly, TMA sections were dewaxed in xylene and then rehydrated in a graded alcohol
series. Antigen retrieval was performed by immersing the
slides in Tris-EDTA buffer (10 mM, pH 9.0) for 10 min
at 125°C in a pressure cooker. Endogenous peroxidase
activity was blocked with 3% hydrogen peroxide in
methanol for 30 min. Non-specific binding sites were
blocked by 5% normal goat serum for 1 h. Slides were
incubated with anti-TAF15 antibody (dilution 1:100;
Abcam) overnight at 4°C in a wet chamber. Slides
were washed with phosphate-buffered saline-tween 20
(0.01%) (PBST) and then incubated with anti-rabbit HRP
conjugated secondary antibody (1:5000; Sigma) for 1 h at
room temperature in a wet chamber. After washing with
PBST, the color was developed with a solution of 0.03%
diaminobenzidine for 2 min at room temperature, and the
sections were counterstained with hematoxylin.

Cells were seeded at a density of 10,000 cells/well
in 12 well plates and cultured for 24 h, 48 h, 72 h, and
96 h. The cells were then trypsinized and counted using
a ViCell cell viability analyzer (Beckman Coulter). Cell
proliferation was normalized as a fold-change of control.
Three independent experiments having triplicates for each
treatment were performed for each cell line.

Co-immunoprecipitation and mass spectrometry
Cell lysates for immunoprecipitation were
prepared using the IP lysis buffer (Thermo Scientific).
Immunoprecipitation with anti-TAF15 antibody bound to
beads was performed by incubating the cross-linked bead
with the lysates overnight. The eluates were analyzed by
LC-MS/MS using label-free quantification techniques.
Normalized spectral counts were analyzed in the Scaffold
Proteome Viewer software [37] and further analyzed for
pathway enrichment using the Ingenuity Pathway Analysis
software.

Western blotting
Cells were lysed using M-PER mammalian protein
extraction reagent (Thermo-Fisher Scientific). Protein
extracts were blotted and probed using antibodies against
TAF15, p-cdc2 (Tyr15), p-Chk2 (Thr68), p-Rb (Ser15
and Ser 807/811), caspase 3, cleaved caspase 3, cleaved
caspase 7, caspase 9, cleaved PARP, phospho-AKT
(Ser 473), total-AKT, p21, phospho-p53 (Ser 15) (Cell
Signaling Technology). To evaluate protein loading, the
blots were probed for GAPDH or Tubulin (Cell Signaling
Technology). The blots were visualized using the
ChemiDoc-MP Imaging System (Bio-Rad) and analyzed
with ImageJ Software.

Cell cycle analysis
The cells were pelleted and washed with phosphatebuffered saline (PBS) and fixed in cold 70% ethanol. Fixed
cells were washed with cold PBS at 4°C and suspended in
Staining Buffer (RNaseA (100 µg/ml, ThermoScientific)
in PBS followed by incubation at 37°C for 30 min.
Cells were stained with 50 µg/ml propidium iodide for
1 h. Propidium iodide fluorescence was measured using
a MACSQuant Analyzer (Miltenyi Biotech), and data
analysis were performed using the FlowJo software.

Colony formation assays

In-vivo near-infrared imaging

Cells were treated with 10 µg/ml of anti-TAF15
antibody and allowed to incubate for 96 h. Cells were
then sub-cultured in six-well plates and irradiated with the
indicated doses of radiation. The shRNA treated cells were
irradiated at 0, 2, 4, 6 and 8Gy. The plates were incubated
for 7–10 days following irradiation, and the colonies were
stained with 0.5% crystal violet. Colonies consisting of 50
or more cells were counted using a StemiVD4 dissecting
microscope (Zeiss). The survival fractions were calculated
after normalizing to the plating efficiency and presented as
surviving fractions relative to control [38–40].
www.oncotarget.com

All animal studies were performed per the
guidelines of the IACUC and with protocols approved
by the Washington University Division of Comparative
Medicine. The TAF15 antibody or isotype control antibody
was labeled with IRDye 800CW as per manufacturer’s
instructions (Licor). Cancers were induced by injecting
A549 or H460 cells in the right hind limbs of nude mice
(Charles River). The cancers were irradiated with three
fractions of 3Gy or 0Gy (sham) over the course of 24 h.
The cancer-bearing mice were then injected with 10 µg
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of labeled antibodies via the tail vein. Mice were imaged
using the Pearl Trilogy small animal imaging system
(Licor). Fluorescence was detected using an 800 nm
channel. Images were analyzed using the Image Studio
software. Background subtracted signal intensity was
plotted using Graph Pad Prism software.
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